WHO Raises Alert Over Severe Lack of Weight-Loss Jabs
Under one in 10 people who could benefit from obesity jabs including Wegovy have access to them, caution the World Health Organization as it issues its first advice on the medications.
With over a billion people worldwide now obese, it is calling for broader and more equitable access to GLP-1 medication.
Per projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a chronic disease that can be addressed with thorough and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal access to the jabs that can aid individuals in losing considerable weight, explains the agency.
Skinny Jab Shortage
Despite the present most optimistic outlook, the manufacturing of such drugs would only suffice for approximately 100 million people β less than 10% of the global need, per the WHO.
The advice calls on nations and manufacturers to increase availability, by strategies such as patent sharing.
The intellectual property rights on semaglutide β the primary component of Novo Nordisk's Wegovy β is scheduled to end in a number of nations in 2026.
How Weight-Loss Injections Function
GLP-1 drugs mimick a biological compound to slow digestion, suppress the appetite and enhance the sense of being full so people eat less.
People commonly start to lose weight after several weeks of beginning the regular doses.
Evidence suggests people may see weight return a year later of discontinuing the treatment, as their normal food cravings come back.
To be above a healthy weight increases your likelihood for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, per the health agency.
